These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 30626376)
21. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972 [TBL] [Abstract][Full Text] [Related]
22. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J; Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758 [TBL] [Abstract][Full Text] [Related]
23. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period. Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Holden SE; Currie CJ; Owens DR Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149 [TBL] [Abstract][Full Text] [Related]
25. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K; Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177 [TBL] [Abstract][Full Text] [Related]
26. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265 [TBL] [Abstract][Full Text] [Related]
27. Fluocinolone acetonide for the treatment of diabetic macular edema. Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565 [TBL] [Abstract][Full Text] [Related]
28. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema. Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study. Ruiz-Moreno JM; Adán A; Lafuente M; Asencio Durán M; Arias Barquet L; García Layana A; Araiz Iribarren J Int Ophthalmol; 2023 Dec; 43(12):4639-4649. PubMed ID: 37697082 [TBL] [Abstract][Full Text] [Related]
38. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Adams OE; Schechet SA; Hariprasad SM Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results. Elbarky AM Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902 [TBL] [Abstract][Full Text] [Related]
40. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]